Immuno-oncology
From the Journals
Tumor surroundings may hold key to TNBC treatment optimization
Investigators say their retrospective study results demonstrate that each TNBC subtype is associated with specific tumor microenvironment profiles...
Conference Coverage
Better overall survival with nivolumab vs. chemo for advanced ESCC
BARCELONA –Nivolumab was associated with improved overall survival and a favorable safety profile vs. chemotherapy...
Conference Coverage
Nivolumab benefit for NSCLC persists at 5-year follow-up
BARCELONA – Nivolumab, compared with docetaxel chemotherapy, led to a fivefold improvement in 5-year overall...
Conference Coverage
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
Conference Coverage
New data further define role of PD-L1 status, immunotherapy in metastatic breast cancer
BARCELONA – PD-L1 status in mTNBC or HER2+ breast cancer appears to identify distinct disease entities with varying likelihood of benefit from...
From the Journals
Pembrolizumab shows promise for relapsed/refractory PMBCL
The findings raise the question of whether PD-1 blockade could resensitize tumors to chemotherapy.
From the Journals
Immunotherapy enables nephrectomy with good outcomes in advanced RCC
Patients able to undergo nephrectomy after receiving immune checkpoint inhibitors had favorable surgical outcomes and pathologic responses in the...
Conference Coverage
Nivolumab boosts overall survival in HCC
BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...
Conference Coverage
Atezolizumab plus chemo gives slight PFS edge in mUC
BARCELONA – Adding the immune checkpoint inhibitor atezolizumab to platinum-based chemotherapy offered a modest PFS benefit over chemotherapy...
From the Journals
Nivolumab-ipilimumab nets long-term survival in advanced melanoma
An update of CheckMate 067 finds that with combination nivolumab and ipilimumab therapy, 52% of patients were alive at 5 years, and the large...
From the Journals
No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCC
Therefore, the treatment should probably be directed by patient preferences, among other things, the investigators said.